Nanoparticle ophthalmic solution improves signs/symptoms of dry eye
A recent study to evaluate the safety and efficacy of a nanoparticle ophthalmic suspension of loteprednol etabonate (Eysuvis, Kala Pharmaceuticals) for the treatment of dry eye disease (DED) found that the suspension rapidly improved both signs and symptoms of the condition and appeared to be safe and well-tolerated, according to a study presented at 2020 AAO Virtual.
Loteprednol etabonate ophthalmic suspension is approved for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye. For the study, a total of 2,871 participants were enrolled in 4 trials: 1,431 were treated with loteprednol etabonate suspension and 1,440 with vehicle 4 times daily (q.i.d.) for 2 weeks. Significant improvements in ocular discomfort severity (ODS) were seen on Day 15 for the loteprednol etabonate suspension vs vehicle in 3 trials: Study 1, Study 2, and Study 4. Significant improvement in ODS was noted as early as Day 8. In addition, significant improvements in conjunctival hyperemia were demonstrated in all 4 trials on Day 15.
No unexpected adverse events occurred in the 4 trials. Installation site pain (5.2% for loteprednol etabonate suspension and 4.4% for vehicle) was the most frequently reported adverse effect. The incidence of treatment-emergent adverse events was comparable between loteprednol etabonate suspension and the vehicle arm. The incidence of IOP increase was low, for loteprednol etabonate suspension (0.6%) and vehicle (0.2%). Test
Reference
Holland EJ, et al. Safety and efficacy of KPI-121 ophthalmic suspension 0.25% for DED in four RCTs. Presented at: AAO 2020 Virtual [Session: PO098].
